Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 19,617 shares, a decrease of 49.3% from the October 15th total of 38,702 shares. Based on an average trading volume of 35,170 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
ENVB has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enveric Biosciences in a report on Thursday, October 15th. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
Read Our Latest Research Report on ENVB
Institutional Investors Weigh In On Enveric Biosciences
An institutional investor recently raised its position in Enveric Biosciences stock. StoneX Group Inc. boosted its holdings in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB – Free Report) by 136.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,986 shares of the company’s stock after acquiring an additional 16,172 shares during the quarter. StoneX Group Inc. owned approximately 0.63% of Enveric Biosciences worth $41,000 at the end of the most recent reporting period. 13.82% of the stock is currently owned by institutional investors.
Enveric Biosciences Price Performance
Shares of NASDAQ:ENVB traded down $0.05 during midday trading on Wednesday, reaching $1.36. The company had a trading volume of 21,266 shares, compared to its average volume of 1,231,871. The stock has a market capitalization of $6.09 million, a P/E ratio of -0.11 and a beta of 1.23. The stock’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.87. Enveric Biosciences has a one year low of $1.17 and a one year high of $13.25.
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.57) earnings per share for the quarter.
Enveric Biosciences Company Profile
Enveric Biosciences is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety. The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.
Read More
- Five stocks we like better than Enveric Biosciences
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
